Peripheral restriction GABA allosteric positive regulator for the treatment of irritable bowel syndrome and other peripheral nervous system disorders
Peripherally restricted GABA-A receptor allosteric modulators address the limitations of current IBS treatments by targeting the peripheral nervous system, effectively treating IBS and other disorders without CNS side effects.
JP7884738B2Active Publication Date: 2026-07-06JOHNS HOPKINS UNIVERSITY +1
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- JOHNS HOPKINS UNIVERSITY
- Filing Date
- 2022-02-01
- Publication Date
- 2026-07-06
AI Technical Summary
Technical Problem
Current treatments for irritable bowel syndrome (IBS) are limited, with existing medications providing only symptom relief and potential severe side effects, and there is a need for alternative approaches that target the peripheral nervous system without crossing the blood-brain barrier.
Method used
Development of peripherally restricted GABA-A receptor allosteric modulators that selectively target the peripheral nervous system, avoiding the blood-brain barrier, to modulate GABAergic neurons and treat conditions like IBS and other systemic diseases.
Benefits of technology
The modulators effectively treat visceral pain and regulate bowel motility in IBS without CNS side effects, providing therapeutic benefits for a range of gastrointestinal and neurological disorders.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 0007884738000001 
Figure 0007884738000002 
Figure 0007884738000003
Abstract
The present disclosure features a chemical compound (e.g., a compound or its pharma- ceutically acceptable salt, or its N-oxide) that is a positive allosteric modulator of one or more GABA-A receptors, e.g., a peripherally restricted positive allosteric modulator of one or more GABA-A receptors that selectively targets the peripheral nervous system and organs of the body and does not substantially cross the blood-brain barrier. The compound is useful, for example, for treating systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders mediated by GABA-A neuronal activity). The present disclosure also features pharmaceutical compositions containing the chemical compounds described herein, and methods of use thereof for treating systemic diseases of the body.
Need to check novelty before this filing date? Find Prior Art